[go: up one dir, main page]

TN2013000378A1 - Anti - sclerostin antibody crystals and formulations thereof - Google Patents

Anti - sclerostin antibody crystals and formulations thereof

Info

Publication number
TN2013000378A1
TN2013000378A1 TNP2013000378A TN2013000378A TN2013000378A1 TN 2013000378 A1 TN2013000378 A1 TN 2013000378A1 TN P2013000378 A TNP2013000378 A TN P2013000378A TN 2013000378 A TN2013000378 A TN 2013000378A TN 2013000378 A1 TN2013000378 A1 TN 2013000378A1
Authority
TN
Tunisia
Prior art keywords
formulations
antibody crystals
sclerostin antibody
crystals
sclerostin
Prior art date
Application number
TNP2013000378A
Other languages
English (en)
Inventor
Christi L Clogston
Twinkle R Christian
Timothy D Osslund
Elisabeth Freeman
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45922852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000378(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TN2013000378A1 publication Critical patent/TN2013000378A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2013000378A 2011-03-25 2013-09-24 Anti - sclerostin antibody crystals and formulations thereof TN2013000378A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467868P 2011-03-25 2011-03-25
PCT/US2012/030364 WO2012135035A1 (fr) 2011-03-25 2012-03-23 Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci

Publications (1)

Publication Number Publication Date
TN2013000378A1 true TN2013000378A1 (en) 2015-01-20

Family

ID=45922852

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000378A TN2013000378A1 (en) 2011-03-25 2013-09-24 Anti - sclerostin antibody crystals and formulations thereof

Country Status (25)

Country Link
US (3) US9145457B2 (fr)
EP (1) EP2688910B1 (fr)
JP (2) JP2014511842A (fr)
KR (1) KR20140018315A (fr)
CN (1) CN103517920B (fr)
AP (1) AP3981A (fr)
AR (1) AR085575A1 (fr)
AU (1) AU2012236962B2 (fr)
BR (1) BR112013024493A2 (fr)
CA (1) CA2830538C (fr)
CL (1) CL2013002743A1 (fr)
CO (1) CO6801637A2 (fr)
CR (1) CR20160147A (fr)
EA (1) EA029956B1 (fr)
IL (1) IL228455A (fr)
MA (1) MA35009B1 (fr)
MX (1) MX338078B (fr)
MY (1) MY170720A (fr)
PE (1) PE20140437A1 (fr)
PH (1) PH12013501971B1 (fr)
SG (2) SG10201701634PA (fr)
TN (1) TN2013000378A1 (fr)
TW (1) TW201247703A (fr)
WO (1) WO2012135035A1 (fr)
ZA (2) ZA201307122B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20170233467A1 (en) * 2014-10-17 2017-08-17 Amgen Inc. Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
CN107090443B (zh) * 2016-02-18 2020-12-08 中国农业大学 一种制备稻瘟病菌促分裂原活化蛋白激酶MoMps1晶体的方法
CN105777858B (zh) * 2016-03-22 2019-09-10 东软威特曼生物科技(南京)有限公司 多种抗体的复合稳定剂及其使用方法
US10279048B2 (en) 2016-07-13 2019-05-07 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3069392A1 (fr) 2017-07-27 2019-01-31 Jiangsu Hengrui Medicine Co., Ltd. Composition pharmaceutique d'anticorps sost et utilisations de celle-ci
CN109112153A (zh) * 2018-09-03 2019-01-01 浙江善测禾骑士生物科技有限公司 一种lpor-y193f突变体蛋白晶体的制备方法
JP7475341B2 (ja) * 2018-10-31 2024-04-26 メルク・シャープ・アンド・ドーム・エルエルシー 抗ヒトｐｄ－１抗体結晶およびその使用方法
EP3876990A4 (fr) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3653702A1 (fr) * 2018-11-15 2020-05-20 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Structure cristalline d'une protéine de réplication codée par un plasmide isolé d'un patient souffrant de sclérose en plaques
WO2021030179A1 (fr) * 2019-08-12 2021-02-18 Amgen Inc. Formulations d'anticorps anti-sclérostine
AU2021251661B2 (en) * 2020-04-06 2025-04-17 Forty Seven, LLC Antibody formulation
CN113444800A (zh) * 2021-06-30 2021-09-28 北京泱深生物信息技术有限公司 基因群作为共预后因子在肾癌预后检测中的应用
CN115804338A (zh) * 2022-12-19 2023-03-17 新疆农业科学院经济作物研究所 一种海岛棉育种方法
CN118236484B (zh) * 2022-12-23 2025-11-04 信立泰(苏州)药业有限公司 一种Romosozumab抗体稳定制剂及其制备方法和用途
CN116375864B (zh) * 2023-05-16 2023-08-08 成都大熊猫繁育研究基地 一种抗大熊猫amh单克隆抗体、杂交瘤细胞株及其应用
WO2025030173A1 (fr) * 2023-08-03 2025-02-06 Next Science IP Holdings Pty Ltd Réduction de l'inflammation dans des tissus de site chirurgical

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
CA2094608A1 (fr) 1990-10-22 1992-04-23 John D. Taylor Construction d'adn pour fournir une therapie a l'arn
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE181575T1 (de) 1991-04-25 1999-07-15 Chugai Pharmaceutical Co Ltd Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
EP0708659A4 (fr) 1993-06-07 2000-08-23 Genentech Inc Polypeptides d'enveloppe du vih
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
DE69535641D1 (de) 1994-04-29 2007-12-27 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
NZ288997A (en) 1994-06-24 1999-01-28 Immunex Corp Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (fr) 1995-06-05 1996-12-12 Gregg A. Hastings Facteur de croissance humain du type ccn
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
AU725238B2 (en) 1996-05-22 2000-10-12 Viventia Biotech Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
EP2380906A2 (fr) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Polypeptides anticorps artificiels
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
WO1999006554A2 (fr) 1997-08-01 1999-02-11 Genset Est 5' pour proteines secretees exprimees dans des tissus musculaires et autres tissus mesodermiques
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1133558B2 (fr) 1998-11-27 2016-04-13 UCB Pharma S.A. Compositions et methodes d'augmentation de la mineralisation de la substance osseuse
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
WO2000044777A1 (fr) 1999-01-29 2000-08-03 Imclone Systems Incorporated Anticorps specifiques au kdr et leurs utilisations
EP1657256B1 (fr) 1999-06-09 2009-10-07 Genentech, Inc. Compositions et méthodes pour traitement des tumeurs
CA2401175A1 (fr) 2000-03-02 2001-09-07 Amgen, Inc. Molecules de type chordine 2 et utilisations de celles-ci
MXPA02011808A (es) 2000-06-01 2003-04-10 Amgen Inc Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
EP1366156A2 (fr) 2000-06-19 2003-12-03 F. Hoffmann-La Roche Ag Polymorphismes genetiques d'osteolevine
AU2002216610A1 (en) 2000-09-01 2002-04-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
KR20100031769A (ko) 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (fr) 2001-03-13 2002-09-13 The Minister Of National Defence Clonage, expression, sequencage et amelioration fonctionnelle de l'anticorps monoclonal a fragment variable et a chaine simple dirige contre le virus de l'encephalomyelite equine du venezuela
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
BRPI0214680B1 (pt) 2001-12-06 2018-09-18 Biocontrol Systems Inc instrumento para uso em monitorar um produto, um ingrediente, um ambiente ou processo, instrumento para detectar emissão de luz de uma amostra e método de monitorar uma amostra de um produto, um ingrediente, um processo ou ambiente
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP4662714B2 (ja) 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
AU2003304107B2 (en) 2002-11-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
ATE540977T1 (de) 2003-03-14 2012-01-15 Ucb Mfg Inc Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
NZ552713A (en) * 2004-07-23 2010-06-25 Genentech Inc Crystallization of anti-VEGF antibodies or fragments thereof using divalent cations
EP1786837B1 (fr) 2004-08-04 2013-05-01 Amgen Inc., Anticorps contre dkk-1
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8541177B2 (en) 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
EP2097450A2 (fr) 2006-11-10 2009-09-09 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
DK3345607T3 (da) 2006-12-29 2022-11-21 Ossifi Mab Llc Fremgangsmåder til ændring af knoglevækst ved indgivelse af sost- eller wise-antagonist eller -agonist
WO2008092894A1 (fr) 2007-02-02 2008-08-07 Novartis Ag Modulateurs de partenaires de liaison de la sclérostine pour traiter des troubles liés aux os
HRP20140108T1 (hr) 2007-03-20 2014-02-28 Eli Lilly & Company Protutijela protiv sklerostina
CA2681752A1 (fr) * 2007-03-29 2008-10-09 Abbott Laboratories Anticorps anti-1l-12 humains cristallins
RU2010107994A (ru) 2007-08-08 2011-09-20 Эбботт Лэборетриз (Us) Композиции и способы кристаллизации антител
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
ES2663077T3 (es) 2007-11-02 2018-04-11 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
EP2227256A1 (fr) 2007-12-14 2010-09-15 Amgen Inc. Procédé de traitement d'une fracture osseuse à l'aide d'anticorps anti-sclérostine
CA2726087A1 (fr) 2008-06-03 2009-12-10 Tariq Ghayur Immunoglobulines a deux domaines variables et leurs utilisations
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
WO2010130830A2 (fr) 2009-05-15 2010-11-18 Ablynx N.V. Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
EP3838922A1 (fr) 2010-10-27 2021-06-23 Amgen Inc. Anticorps dkk1 et procédés d'utilisation
CA2858974A1 (fr) 2011-12-28 2013-07-04 Amgen Inc. Methode de traitement d'une perte osseuse alveolaire au moyen d'anticorps anti-sclerostine

Also Published As

Publication number Publication date
ZA201608660B (en) 2018-05-30
CA2830538C (fr) 2020-05-12
CO6801637A2 (es) 2013-11-29
IL228455A (en) 2017-05-29
ZA201307122B (en) 2017-08-30
MY170720A (en) 2019-08-27
BR112013024493A2 (pt) 2018-06-26
JP2017125020A (ja) 2017-07-20
AU2012236962B2 (en) 2017-05-11
MX338078B (es) 2016-04-01
JP2014511842A (ja) 2014-05-19
US20140105909A1 (en) 2014-04-17
SG10201701634PA (en) 2017-04-27
TW201247703A (en) 2012-12-01
CL2013002743A1 (es) 2014-05-23
PH12013501971A1 (en) 2014-01-06
CN103517920B (zh) 2018-04-17
AP2013007135A0 (en) 2013-09-30
CR20160147A (es) 2016-08-03
EA201391389A1 (ru) 2014-03-31
US9617333B2 (en) 2017-04-11
IL228455A0 (en) 2013-12-31
EP2688910A1 (fr) 2014-01-29
SG193610A1 (en) 2013-11-29
US9145457B2 (en) 2015-09-29
MX2013011012A (es) 2014-04-25
JP6412964B2 (ja) 2018-10-24
PH12013501971B1 (en) 2018-08-31
US20160083460A1 (en) 2016-03-24
MA35009B1 (fr) 2014-04-03
EA029956B1 (ru) 2018-06-29
KR20140018315A (ko) 2014-02-12
CA2830538A1 (fr) 2012-10-04
PE20140437A1 (es) 2014-04-17
WO2012135035A1 (fr) 2012-10-04
US20170210792A1 (en) 2017-07-27
US9920114B2 (en) 2018-03-20
CN103517920A (zh) 2014-01-15
AU2012236962A1 (en) 2013-10-10
AP3981A (en) 2017-01-05
NZ615624A (en) 2015-10-30
AR085575A1 (es) 2013-10-09
EP2688910B1 (fr) 2019-05-29

Similar Documents

Publication Publication Date Title
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MY178142A (en) Anti-phf-tau antibodies and their uses
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2019002979A (es) Formulaciones de anticuerpos.
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX347020B (es) Anticuerpo contra el csf-1r.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
SG10201804338PA (en) Anti-fcrh5 antibodies
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
PH12014500904B1 (en) Antibody formulations and methods
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
WO2012166659A3 (fr) Anticorps anti-emr1
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства